Status:
TERMINATED
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
Lead Sponsor:
Repros Therapeutics Inc.
Conditions:
Uterine Fibroids
Eligibility:
FEMALE
18-48 years
Phase:
PHASE3
Brief Summary
The safety of Proellex 25 and 50 mg administered once daily for three treatment cycles (four months each) will be evaluated.
Detailed Description
Subjects will be randomized to either Proellex dose, 25 mg or 50 mg, in a 1:1 ratio. Subjects will receive drug for a four (4) month cycle of therapy three (3) times, each treatment cycle being separa...
Eligibility Criteria
Inclusion
- Speak, read and understand English or Spanish;
- Not have undergone hysterectomy, uterine arterial embolization or endometrial ablation therapy (previous myomectomy is acceptable) for any cause and no surgical interventions for uterine fibroids (e.g. hysterectomy, myomectomy, uterine arterial embolization) are planned or anticipated during the study;
- One uterine fibroid must be identifiable and measurable by transvaginal ultrasound;
- Menstrual cycle lasting from 24 to 36 days;
- History of excessive menstrual bleeding;
- Negative urine pregnancy test at screening.
- Additional inclusion criteria may apply.
Exclusion
- Six months or more (immediately prior to Screening Visit) without a menstrual period;
- Prior hysterectomy;
- Prior bilateral oophorectomy;
- Pregnant or lactating females or women who are attempting or expecting to become pregnant at any time during the study;
- Documented endometriosis, active pelvic inflammatory disease (PID), platelet dysfunction, or Von Willebrand's Disease;
- Any history or diagnosis of gynecological cancer or cervical dysplasia of any grade including atypical squamous cells of undetermined significance (ASCUS) associated with Human Papilloma Virus (HPV);
- Subject with diagnosed or suspected carcinoma of the breast, reproductive organs or any other organ system;
- Subject with known active infection with HIV, Hepatitis A, B or C, Gonorrhea, or Chlamydia or previous history of auto-immune disease or positive serum antinuclear antibodies.
- Additional exclusion criteria may apply.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT00737282
Start Date
October 1 2008
End Date
August 1 2009
Last Update
August 21 2014
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Lynn Institute of the Ozarks
Little Rock, Arkansas, United States, 72205
2
AWC Clinical Trials LLC
Little Rock, Arkansas, United States, 72223
3
Impact Clinical Trials
Beverly Hills, California, United States, 80211
4
Genesis Center for Clinical Research
San Diego, California, United States, 92103